“…The FXR-SHP-SREBP-1c pathway does not appear to play a role in this process [25, 29–32]. Instead, other genes/pathways, including FGF21 [43], ChREBP [33], PPARα [36, 41], and AKR1B7 [34] may play a role in FXR-mediated reduction in hepatic triglyceride levels. Activation of FXR regulates plasma cholesterol and triglyceride levels through modulating several genes, including SR-BI [19], LDLR [16], Syndecan-1[39], VLDLR [38], ApoCII, ApoCIII [37] and ANGPTL3 [25].…”